Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

• Publication date

  2013-03-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1002/wnan.1209PMID 23335566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanocarriers as an Emerging Platform for Cancer Therapy

  2020cited by this paper
• Cancer nanomedicines: so many papers and so few drugs!

  2013cited by this paper
• Physicochemical properties determine nanomaterial cellular uptake, transport, and fate.

  2013cited by this paper
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

  2012cited by this paper
• 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

  2012cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Bio-inspired, bioengineered and biomimetic drug delivery carriers

  2011cited by this paper
• A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

  2011cited by this paper
• A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.

  2011cited by this paper
• Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.

  2010cited by this paper
• Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

  2010cited by this paper
• Biocompatibility and drug delivery systems

  2010cited by this paper
• Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

  2010cited by this paper
• Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.

  2010cited by this paper
• The status of platinum anticancer drugs in the clinic and in clinical trials.

  2010cited by this paper
• Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.

  2009cited by this paper
• Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture.

  2009cited by this paper
• XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

  2009cited by this paper
• ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.

  2009cited by this paper
• Camptothecins: a SAR/QSAR study.

  2009cited by this paper
• Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility

  2009cited by this paper
• Polymeric micellar delivery systems in oncology.

  2008cited by this paper
• Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.

  2008cited by this paper
• Nanoparticles in Medicine: Therapeutic Applications and Developments

  2008cited by this paper
• Prodrug Strategies in Anticancer Chemotherapy

  2008cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• Nanocarriers as an emerging platform for cancer therapy.

  2007cited by this paper
• Direct cellular responses to platinum-induced DNA damage.

  2007cited by this paper
• Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

  2007cited by this paper
• First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN).

  2007cited by this paper
• Current management strategies for ovarian cancer.

  2007cited by this paper
• Central nervous system tumors.

  2007cited by this paper
• Platinum complexes as anticancer agents.

  2006cited by this paper
• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

  2006cited by this paper
• Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Strategies for optimizing combinations of molecularly targeted anticancer agents

  2006cited by this paper
• Polymer conjugates as anticancer nanomedicines

  2006cited by this paper
• A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

  2006cited by this paper
• Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.

  2006cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006cited by this paper
• New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

  2006cited by this paper
• Recent advances with liposomes as pharmaceutical carriers

  2005cited by this paper
• Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

  2004cited by this paper
• A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

  2004cited by this paper
• Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).

  2004cited by this paper
• A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

  2004cited by this paper
• A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

  2003cited by this paper
• Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins.

  2003cited by this paper
• Dendritic molecular capsules for hydrophobic compounds.

  2003cited by this paper
• Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.

  2003cited by this paper
• The dawning era of polymer therapeutics

  2003cited by this paper
• Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma

  2003cited by this paper
• Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture.

  2002cited by this paper
• Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

  2002cited by this paper
• A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

  2002cited by this paper
• Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.

  2001cited by this paper
• Cytochrome P-450 3A4: regulation and role in drug metabolism.

  1999cited by this paper
• Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

  1999cited by this paper
• Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity.

  1998cited by this paper
• Gastrointestinal toxicity or irinotecan.

  1998cited by this paper
• The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.

  1994cited by this paper
• Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.

  1994cited by this paper
• Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.

  1993cited by this paper
• Platinum complex-induced dysfunction of cultured renal proximal tubule cells

  1993cited by this paper
• Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles.

  1992cited by this paper
• Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.

  1991cited by this paper
• Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).

  1990cited by this paper
• Mechanisms and consequences of cellular cholesterol exchange and transfer.

  1987cited by this paper
• A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

  1986cited by this paper
• Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

  1966cited by this paper

• Site-specific delivery of cisplatin and paclitaxel mediated by liposomes: A promising approach in cancer chemotherapy.

  2023cites this paper
• Supramolecular Combination Cancer Therapy Based on Macrocyclic Supramolecular Materials

  2022cites this paper
• Recent advancements on hyperthermia driven controlled drug delivery from nanotherapeutics.

  2022cites this paper
• IMPROVEMENT OF THE MICROFLUIDIC DEVICE FOR THE GENERATION OF MONODISPERSE MICROBUBBLES AS DRUG TRANSPORT SYSTEMS

  2021cites this paper
• Antitumor potential of cisplatin loaded into SBA-15 mesoporous silica nanoparticles against B16F1 melanoma cells: in vitro and in vivo studies.

  2021cites this paper
• Biological Applications of Platinum-Based Nanoclusters

  2020cites this paper
• Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.

  2020cites this paper
• Hyperthermia and smart drug delivery systems for solid tumor therapy.

  2020cites this paper
• Hyperthermia and Temperature-Sensitive Nanomaterials for Spatiotemporal Drug Delivery to Solid Tumors

  2020cites this paper
• Recent Advances in the Synthesis, Properties, and Biological Applications of Platinum Nanoclusters

  2019cites this paper
• Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer.

  2019cites this paper
• Amino Acid-functionalized Hollow Mesoporous Silica Nanospheres as Efficient Biocompatible Drug Carriers for Anticancer Applications.

  2019cites this paper
• Controlled micelle conjugation via charged peptide amphiphiles

  2019cites this paper
• Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials

  2018cites this paper
• Fully synthetic macromolecular prodrug chemotherapeutics with EGFR targeting and controlled camptothecin release kinetics.

  2018cites this paper
• Selective bio-labeling and induced apoptosis of hematopoietic cancer cells using dual-functional polyethylenimine-caged platinum nanoclusters.

  2018cites this paper
• Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.

  2018cites this paper
• Multifunctional platinum-based nanoparticles for biomedical applications.

  2017cites this paper
• Targeting the Brain with Nanomedicine.

  2017cites this paper
• Block ionomer micellar nanoparticles from double hydrophilic copolymers, classifications and promises for delivery of cancer chemotherapeutics

  2017cites this paper
• Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol‐modified phospholipids

  2017cites this paper
• pH and redox dual-sensitive polysaccharide nanoparticles for the efficient delivery of doxorubicin.

  2017cites this paper
• A Nano-in-Nano Polymer-Dendrimer Nanoparticle-Based Nanosystem for Controlled Multidrug Delivery.

  2017cites this paper
• Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.

  2016cites this paper
• Targeted Drug Delivery System for Platinum-based Anticancer Drugs.

  2016cites this paper
• Fiber Based Approaches as Medicine Delivery Systems.

  2016cites this paper
• Nanoliposomal irinotecan for treating pancreatic cancer

  2016cites this paper
• Synthesis of an esterase‐sensitive degradable polyester as facile drug carrier for cancer therapy

  2016cites this paper
• SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells

  2016cites this paper
• Synthesis of the first POSS cage–anthracycline conjugates via amide bonds

  2016cites this paper
• Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials

  2016cites this paper
• Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

  2016cites this paper
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

  2016cites this paper
• Tunable conjugation densities of camptothecin on hyaluronic acid for tumor targeting and reduction-triggered release.

  2016cites this paper
• Preparation and Antiproliferative Activity of Liposomes Containing a Combination of Cisplatin and Procainamide Hydrochloride.

  2016cites this paper
• Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer.

  2016cites this paper
• Micellization of antineoplastic agent to significantly upregulate efficacy and security.

  2015cites this paper
• Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

  2015cites this paper
• A multifunctional PEG-PLL drug conjugate forming redox-responsive nanoparticles for intracellular drug delivery.

  2015cites this paper
• Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex.

  2015cites this paper
• Release of copper complexes from a nanostructured sol–gel titania for cancer treatment

  2015cites this paper
• Targeted endothelial nanomedicine for common acute pathological conditions.

  2015cites this paper
• Cisplatin-Induced Formation of Biocompatible and Biodegradable Polypeptide-Based Vesicles for Targeted Anticancer Drug Delivery.

  2015cites this paper
• Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.

  2015cites this paper
• Rational Design of Multifunctional Nanoscale Self-Assembled Soft Materials for Biomedical Delivery Application

  2014cites this paper
• Noncovalent interaction-assisted polymeric micelles for controlled drug delivery.

  2014cites this paper
• PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system

  2014cites this paper
• Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm

  2014cites this paper
• Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment

  2014cites this paper
• A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.

  2014cites this paper
• Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy.

  2013cites this paper
• Nanopartículas e suas aplicações em Ciências Farmacêuticas

  2013cites this paper
• Novel and emerging therapies safeguarding health of humans and their companion animals: a review.

  2013cites this paper